Micropharma, which is involved in the development of probiotics, has announced that it has filed a number of patents for its probiotic technologies.
Probiotics are bacteria that offer a health benefit to the host. They are being studied to determine if they may have a more significant role in helping to maintain and improve health and wellness through the gut.
Micropharma president and chief executive officer Ryan Jones said that Micropharma has invested significantly over the past several years in research and development of probiotic products.
"By patenting our products like Cardioviva™, it helps us guarantee to consumers that they will get a rigorously tested, proven probiotic product," Jones added.
Micropharma plan to launch a portfolio of natural supplements and food ingredient solutions aimed at addressing specific health markers to help maintain and improve health and wellness.
The company plans to out-license these products to partners for commercialization in the medical food, consumer healthcare, and food ingredient markets.
